| 62.49 0.01 (0.02%) | 02-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 73.01 | 1-year : | 85.27 |
| Resists | First : | 62.5 | Second : | 73.01 |
| Pivot price | 62.47  |
|||
| Supports | First : | 62.24 |
Second : | 62.08 |
| MAs | MA(5) : | 62.49 | MA(20) : | 62.43 |
| MA(100) : | 42.02 |
MA(250) : | 0 | |
| MACD | MACD : | 0.9  |
Signal : | 1.3 |
| %K %D | K(14,3) : | 84.3 |
D(3) : | 87.7 |
| RSI | RSI(14): 88.2 | |||
| 52-week | High : | 62.5 | Low : | 17.95 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RYZB ] has closed below upper band by 36.2%. Bollinger Bands are 98.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for {EMPTY} bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 62.64 - 62.94 | 62.94 - 63.19 |
| Low: | 61.62 - 62.05 | 62.05 - 62.39 |
| Close: | 61.89 - 62.54 | 62.54 - 63.06 |
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Mon, 26 Feb 2024
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical ... - Business Wire
Fri, 23 Feb 2024
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer - Business Wire
Wed, 17 Jan 2024
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates BRBS, RYZB, VIA, CPE - GlobeNewswire
Mon, 01 Jan 2024
Bristol Myers Squibb Acquires RayzeBio - San Diego Business Journal
Tue, 26 Dec 2023
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio - Business Wire
Tue, 19 Sep 2023
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 89.7 (%) |
| Shares Short | 848 (K) |
| Shares Short P.Month | 822 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -57.87 |
| PEG Ratio | 0 |
| Price to Book value | 6.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -66.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|